LT3295951T - Anti-pvrig antikūnai ir naudojimo būdai - Google Patents

Anti-pvrig antikūnai ir naudojimo būdai

Info

Publication number
LT3295951T
LT3295951T LTEP17192325.3T LT17192325T LT3295951T LT 3295951 T LT3295951 T LT 3295951T LT 17192325 T LT17192325 T LT 17192325T LT 3295951 T LT3295951 T LT 3295951T
Authority
LT
Lithuania
Prior art keywords
methods
pvrig antibodies
pvrig
antibodies
Prior art date
Application number
LTEP17192325.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Mark White
Sandeep Kumar
Christopher Chan
Spencer LIANG
Lance STAPLETON
Andrew W. DRAKE
Yosi GOZLAN
Ilan Vaknin
Shirley Sameah-Greenwald
Liat Dassa
Zohar Tiran
Gad S. Cojocaru
Leonard Presta
Richard Theolis
Original Assignee
Compugen Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55453315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3295951(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Compugen Ltd. filed Critical Compugen Ltd.
Publication of LT3295951T publication Critical patent/LT3295951T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
LTEP17192325.3T 2015-02-19 2016-02-19 Anti-pvrig antikūnai ir naudojimo būdai LT3295951T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118208P 2015-02-19 2015-02-19
US201562141120P 2015-03-31 2015-03-31
US201562235823P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
LT3295951T true LT3295951T (lt) 2020-09-25

Family

ID=55453315

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP19214231.3T LT3653221T (lt) 2015-02-19 2016-02-19 Anti-pvrig antikūnai ir naudojimo būdai
LTEP16707603.3T LT3258951T (lt) 2015-02-19 2016-02-19 Anti-pvrig antikūnai ir jų panaudojimo būdai
LTEP17192325.3T LT3295951T (lt) 2015-02-19 2016-02-19 Anti-pvrig antikūnai ir naudojimo būdai

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP19214231.3T LT3653221T (lt) 2015-02-19 2016-02-19 Anti-pvrig antikūnai ir naudojimo būdai
LTEP16707603.3T LT3258951T (lt) 2015-02-19 2016-02-19 Anti-pvrig antikūnai ir jų panaudojimo būdai

Country Status (21)

Country Link
US (8) US10227408B2 (enExample)
EP (4) EP3258951B1 (enExample)
JP (2) JP7115856B2 (enExample)
KR (2) KR20240090732A (enExample)
CN (2) CN107580500B (enExample)
AU (3) AU2016219835B2 (enExample)
CY (2) CY1122970T1 (enExample)
DK (3) DK3258951T3 (enExample)
ES (3) ES2929293T3 (enExample)
HR (3) HRP20221284T1 (enExample)
HU (3) HUE049791T2 (enExample)
IL (2) IL254039B2 (enExample)
LT (3) LT3653221T (enExample)
MX (2) MX374853B (enExample)
PL (3) PL3258951T3 (enExample)
PT (3) PT3258951T (enExample)
RU (1) RU2732042C2 (enExample)
SG (1) SG11201706583PA (enExample)
SI (2) SI3295951T1 (enExample)
WO (1) WO2016134333A1 (enExample)
ZA (1) ZA201706323B (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3243494B2 (ja) 1999-05-18 2002-01-07 独立行政法人産業技術総合研究所 チオフェン水素化脱硫用触媒及びその製造方法
JP5641508B2 (ja) * 2010-02-23 2014-12-17 国立大学法人 東京大学 樹状細胞免疫受容体刺激剤
CA2933707A1 (en) 2013-12-20 2015-06-25 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
PT3258951T (pt) 2015-02-19 2020-08-18 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
DK3259597T3 (da) 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
US11078278B2 (en) * 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
CN108137702B (zh) * 2015-08-28 2023-01-06 艾利妥 抗siglec-7抗体及其使用方法
CA2997179A1 (en) * 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN110088132B (zh) * 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
BR112019005633A8 (pt) 2016-09-23 2023-04-11 Hutchinson Fred Cancer Res Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos
SG11201908527SA (en) 2017-03-15 2019-10-30 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN121159691A (zh) 2017-05-12 2025-12-19 哈普恩治疗公司 间皮素结合蛋白质
AU2018271991B2 (en) 2017-05-24 2024-07-11 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
CA3064331A1 (en) * 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
WO2019033057A1 (en) 2017-08-11 2019-02-14 Fred Hutchinson Cancer Research Center SPECIFIC BRAF TCR AND USES THEREOF
US20200262894A1 (en) 2017-09-06 2020-08-20 Fred Hutchinson Cancer Research Center Strep-tag specific binding proteins and uses thereof
AU2018327225A1 (en) 2017-09-06 2020-02-27 Fred Hutchinson Cancer Center Strep-tag specific chimeric receptors and uses thereof
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
EA202090817A1 (ru) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. Триспецифические белки и способы их применения
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
WO2019175222A1 (en) 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
JP2021522801A (ja) 2018-05-09 2021-09-02 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトネクチン４に特異的な抗体
CA3106380A1 (en) 2018-05-31 2019-12-05 Glyconex Inc. Therapeutic antibodies
KR20210016448A (ko) * 2018-06-01 2021-02-15 컴퓨젠 엘티디. 항-pvrig/항-tigit 이중특이적 항체 및 사용 방법
WO2019236965A1 (en) 2018-06-08 2019-12-12 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
JP7072715B2 (ja) * 2018-07-20 2022-05-20 サーフィス オンコロジー インコーポレイテッド 抗ｃｄ１１２ｒ組成物及び方法
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
KR20210049119A (ko) 2018-08-22 2021-05-04 프레드 헛친슨 켄서 리서치 센터 Kras 또는 her2 항원을 표적으로 하는 면역요법
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
AU2019338602A1 (en) * 2018-09-14 2021-04-01 Elanco Us Inc. Anti-IL4 receptor antibodies for veterinary use
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
KR20210102231A (ko) 2018-11-09 2021-08-19 프레드 헛친슨 켄서 리서치 센터 메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도
JP7498714B2 (ja) 2018-12-19 2024-06-12 ヒューマブス・バイオメッド・ソシエテ・アノニム Ｂ型肝炎ウイルスを中和する抗体およびその使用
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
TWI870382B (zh) * 2019-02-06 2025-01-21 美商開拓免疫醫療公司 抗trem1抗體及相關方法
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
KR20210130189A (ko) 2019-02-20 2021-10-29 프레드 헛친슨 켄서 리서치 센터 Ras 신항원에 특이적인 결합 단백질 및 이의 용도
CN113784978B (zh) 2019-03-11 2025-07-25 弗雷德哈钦森癌症中心 高亲合力wt1 t细胞受体及其用途
KR20220041881A (ko) 2019-07-29 2022-04-01 컴퓨젠 엘티디. 항-pvrig 항체 제제 및 이의 용도
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7737978B2 (ja) 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
AU2020336980B2 (en) 2019-08-29 2025-07-10 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis B virus infection
CN114980922A (zh) 2019-11-04 2022-08-30 康姆普根有限公司 抗pvrig抗体制剂和抗pd-1抗体的组合疗法
JP7657794B2 (ja) * 2019-11-15 2025-04-07 サーフェス、アンコロジー、インコーポレイテッド 免疫療法のための組成物及び方法
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
TWI873311B (zh) * 2020-03-13 2025-02-21 大陸商江蘇恆瑞醫藥股份有限公司 Ｐｖｒｉｇ結合蛋白及其醫藥用途
KR20230042023A (ko) 2020-06-24 2023-03-27 비르 바이오테크놀로지, 인코포레이티드 조작된 b형 간염 바이러스 중화 항체 및 이의 용도
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
TW202216778A (zh) * 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20250018036A1 (en) 2020-09-24 2025-01-16 Fred Hutchinson Cancer Center Immunotherapy targeting sox2 antigens
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
AU2020469045A1 (en) * 2020-09-25 2023-04-27 Suzhou Ersheng Biopharmaceutical Co., Ltd Detection method for tumor-specific t cells
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
US20230400467A1 (en) * 2020-10-26 2023-12-14 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN112433055A (zh) * 2020-11-04 2021-03-02 上海药明生物技术有限公司 一种基于报告基因方法检测pvrig抗体的生物学活性的方法
WO2022132836A2 (en) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022164805A1 (en) 2021-01-26 2022-08-04 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
US20240082397A1 (en) 2021-01-28 2024-03-14 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
US20240076373A1 (en) 2021-01-28 2024-03-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
US20240309087A1 (en) * 2021-02-09 2024-09-19 Shanghai Junshi Biosciences Co., Ltd. Anti-cd112r antibody and use thereof
CN116829591A (zh) 2021-02-11 2023-09-29 奈克汀治疗有限公司 针对cd112r的抗体及其用途
CN115925917A (zh) * 2021-03-08 2023-04-07 合肥天港免疫药物有限公司 抗pvrig蛋白抗体或抗体片段及其用途
EP4314060A1 (en) 2021-03-31 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
WO2022258049A1 (en) * 2021-06-10 2022-12-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric pvrig
EP4588524A3 (en) 2021-07-01 2025-09-03 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
WO2023288281A2 (en) 2021-07-15 2023-01-19 Fred Hutchinson Cancer Center Chimeric polypeptides
EP4378954A4 (en) 2021-07-30 2025-05-21 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
TW202327649A (zh) * 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白聯合免疫檢查點抑制劑用於治療癌症
US20240376207A1 (en) 2021-09-15 2024-11-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
CA3231320A1 (en) 2021-09-15 2023-03-23 Zhiliang CAO Protein specifically binding to pd-1 and pharmaceutical use thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CN115819582A (zh) * 2021-12-24 2023-03-21 合肥天港免疫药物有限公司 Pvrig的抗体或其抗原结合片段及其应用
CN114644711B (zh) * 2022-03-07 2025-03-04 南京诺艾新生物技术有限公司 重组抗人pvrig抗体及应用
EP4493195A1 (en) 2022-03-15 2025-01-22 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
EP4245374A3 (en) * 2022-03-18 2024-07-10 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN116925222A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
CN116925233A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
IL317588A (en) * 2022-06-14 2025-02-01 Ablynx Nv Single immunoglobulin variable sites targeting the T cell receptor
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2024032700A1 (en) * 2022-08-10 2024-02-15 Beigene, Ltd. Anti-pvrig antibodies and methods of use
EP4582450A1 (en) * 2022-08-31 2025-07-09 CSPC Megalith Biopharmaceutical Co., Ltd. Anti-pvrig antibody and application thereof
CN120187755A (zh) * 2022-11-10 2025-06-20 华辉安健（北京）生物科技有限公司 抗cd112r抗体及其用途
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
WO2024140031A1 (zh) 2022-12-30 2024-07-04 杭州中美华东制药有限公司 一种靶向cd112r的抗体或其抗原结合片段及其应用
WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
TW202502812A (zh) * 2023-06-06 2025-01-16 大陸商上海藥明生物技術有限公司 抗pvrig抗體及其用途
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
CN119591715B (zh) * 2023-12-22 2025-10-31 华润生物医药有限公司 抗pvrig抗体及其用途
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
CN119193693B (zh) * 2024-08-06 2025-06-13 湖南农业大学 重组质粒及其制备方法、蛋白组合物、用途、疫苗、组合疫苗
CN120058919B (zh) * 2025-04-29 2025-07-18 浙江大学杭州国际科创中心 抗裂谷热病毒Gn蛋白的单抗及在病毒检测中的应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
WO2000052151A2 (en) 1999-03-05 2000-09-08 Incyte Pharmaceuticals, Inc. Human secretory proteins
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
WO2002090520A2 (en) 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003290432A1 (en) * 2002-12-26 2004-07-22 Asahi Kasei Pharma Corporation T cell activating gene
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL2177537T3 (pl) 2004-01-09 2012-06-29 Pfizer Przeciwciała przeciw MadCAM
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7622265B2 (en) 2005-02-22 2009-11-24 Genentech, Inc. Methods and compositions for modulating prostasin
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
EP2007806A2 (en) 2006-04-13 2008-12-31 ZymoGenetics, Inc. Tetramerizing polypeptides and methods of use
AU2007240491A1 (en) 2006-04-13 2007-11-01 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
US20090318376A1 (en) 2006-06-15 2009-12-24 Korea Research Institute Of Bioscience And Biotechnology High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
PE20081456A1 (es) * 2006-10-06 2008-11-27 Takeda Pharmaceutical Anticuerpo monoclonal contra nectina 2
WO2009017679A2 (en) * 2007-07-31 2009-02-05 Merck & Co., Inc. Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
ES2758126T3 (es) 2008-04-09 2020-05-04 Genentech Inc Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2412808B1 (en) 2009-03-25 2016-09-07 Tohoku University Lh-type bispecific antibody
US20110217297A1 (en) 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2643019B1 (en) 2010-11-24 2019-01-02 Lexicon Pharmaceuticals, Inc. Antibodies to notum pectinacetylesterase
WO2012129488A2 (en) 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
EP2710147A1 (en) 2011-05-18 2014-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
WO2012178128A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
TW201323440A (zh) 2011-10-24 2013-06-16 Abbvie Inc 抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
WO2013184912A2 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
CN103073644B (zh) 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
MX384142B (es) 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR102248804B1 (ko) 2014-03-12 2021-05-11 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
WO2015136052A1 (en) 2014-03-14 2015-09-17 Innate Pharma Humanized antibodies with increased stability
AU2015289621A1 (en) 2014-07-16 2017-01-12 Genentech, Inc. Methods of treating cancer using TIGIT inhibitors and anti-cancer agents
CN113583131B (zh) 2014-08-19 2024-09-03 默沙东有限责任公司 抗tigit抗体
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP3215536A1 (en) 2014-11-06 2017-09-13 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and tigit inhibitors
EP3221358B1 (en) 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
WO2016081746A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
DK3259597T3 (da) 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
PT3258951T (pt) 2015-02-19 2020-08-18 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
CR20220186A (es) 2015-09-25 2022-07-07 Genentech Inc ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225)
AU2016331052B2 (en) 2015-10-01 2023-08-03 Potenza Therapeutics, Inc. Anti-TIGIT antigen-binding proteins and methods of use thereof
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2018017864A2 (en) 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
MX2019012381A (es) 2017-05-18 2020-01-23 Hoffmann La Roche Reduccion de reaccion secundaria relacionada con la aplicacion de un anticuerpo terapeutico.
CA3064331A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
CA3089906A1 (en) 2018-02-08 2019-08-15 Amgen Inc. Low ph pharmaceutical antibody formulation
CN114980922A (zh) 2019-11-04 2022-08-30 康姆普根有限公司 抗pvrig抗体制剂和抗pd-1抗体的组合疗法
US12462008B2 (en) 2021-04-23 2025-11-04 Beijing Boe Technology Development Co., Ltd. Unlocking control method and device, electronic apparatus, and computer-readable storage medium

Also Published As

Publication number Publication date
EP4129320A1 (en) 2023-02-08
HUE061084T2 (hu) 2023-05-28
ES2929293T3 (es) 2022-11-28
HK1247569A1 (en) 2018-09-28
US20240101669A1 (en) 2024-03-28
LT3258951T (lt) 2020-05-11
AU2020264349B2 (en) 2024-05-02
CY1122970T1 (el) 2021-10-29
PL3653221T3 (pl) 2022-12-19
CY1123259T1 (el) 2021-12-31
PT3653221T (pt) 2022-11-08
RU2020128686A (ru) 2020-10-13
SG11201706583PA (en) 2017-09-28
US20250333503A1 (en) 2025-10-30
KR20170137067A (ko) 2017-12-12
EP3653221A1 (en) 2020-05-20
SI3258951T1 (sl) 2020-07-31
SI3295951T1 (sl) 2020-10-30
DK3653221T3 (da) 2022-10-24
IL304117A (en) 2023-09-01
PT3295951T (pt) 2020-07-21
EP3258951A1 (en) 2017-12-27
IL254039A0 (en) 2017-10-31
PL3258951T3 (pl) 2020-07-27
HK1247568A1 (en) 2018-09-28
US10351625B2 (en) 2019-07-16
AU2024202336A1 (en) 2024-05-16
PL3295951T3 (pl) 2020-10-05
HRP20221284T1 (hr) 2022-12-23
CA2976926A1 (en) 2016-08-25
US11795220B2 (en) 2023-10-24
RU2017132214A3 (enExample) 2019-08-28
ES2806800T3 (es) 2021-02-18
MX2017010667A (es) 2018-08-15
CN107580500A (zh) 2018-01-12
US20160244521A1 (en) 2016-08-25
DK3653221T5 (da) 2024-08-26
ES2786651T3 (es) 2020-10-13
JP2022106783A (ja) 2022-07-20
MX374853B (es) 2025-03-06
HRP20200572T1 (hr) 2020-08-21
KR102669294B1 (ko) 2024-05-23
JP7115856B2 (ja) 2022-08-09
US20210188974A1 (en) 2021-06-24
EP3258951B1 (en) 2020-01-29
EP3295951A1 (en) 2018-03-21
AU2016219835B2 (en) 2020-12-03
HUE049791T2 (hu) 2020-10-28
IL254039B2 (en) 2023-12-01
LT3653221T (lt) 2022-11-10
RU2017132214A (ru) 2019-03-19
US20180244774A1 (en) 2018-08-30
HUE049032T2 (hu) 2020-08-28
US11623955B2 (en) 2023-04-11
US20200148769A1 (en) 2020-05-14
CN107580500B (zh) 2023-05-30
AU2016219835A1 (en) 2017-09-14
DK3295951T3 (da) 2020-07-20
US9714289B2 (en) 2017-07-25
DK3258951T3 (da) 2020-04-06
IL254039B1 (en) 2023-08-01
WO2016134333A1 (en) 2016-08-25
HRP20201066T1 (hr) 2021-02-05
US20170081408A1 (en) 2017-03-23
WO2016134333A9 (en) 2017-02-02
PT3258951T (pt) 2020-08-18
ZA201706323B (en) 2020-05-27
MX2020009461A (es) 2021-02-17
RU2732042C2 (ru) 2020-09-10
US12312404B2 (en) 2025-05-27
US20170029504A1 (en) 2017-02-02
JP2018512443A (ja) 2018-05-17
US10227408B2 (en) 2019-03-12
EP3295951B1 (en) 2020-04-22
EP3653221B1 (en) 2022-08-03
CN115350275A (zh) 2022-11-18
US11220542B2 (en) 2022-01-11
KR20240090732A (ko) 2024-06-21
AU2020264349A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
IL279606A (en) Anti-TREM2 antibodies and methods of using them
LT3295951T (lt) Anti-pvrig antikūnai ir naudojimo būdai
LT3618863T (lt) Anti-tigit antikūnai ir jų panaudojimo būdai
LT3601358T (lt) Anti-trem2 antikūnai ir jų naudojimo metodai
IL251970B (en) Anti-cd79b antibodies and methods of use
IL259495A (en) Antibodies and methods for using them
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
LT3525583T (lt) Anti-c1s antikūnai ir jų naudojimo būdai
IL249092A0 (en) Anti-gitr antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
LT3303396T (lt) Antikūnai prieš ox40 ir jų panaudojimo būdai
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
IL313083A (en) Terlipressin compositions and their methods of use